Trial Testing FCR001 for Severe Scleroderma Underway in Michigan

Trial Testing FCR001 for Severe Scleroderma Underway in Michigan

313233

Trial Testing FCR001 for Severe Scleroderma Underway in Michigan

Talaris Therapeutics has launched a Phase 2 clinical trial to test its treatment candidate FCR001 for people with diffuse cutaneous systemic sclerosis (dcSSc), a severe form of scleroderma. The trial, called FREEDOM-3 (NCT05098145), is now underway at the University of Michigan, where adults with rapidly progressing dcSSc who are at risk of organ failure will be screened for potential eligibility. “I am delighted that the University of Michigan is the first activated site to participate…

You must be logged in to read/download the full post.